NOV 20, 2013 10:00 AM PST

Navigating the Evolving Molecular Diagnostic Reimbursement Landscape to Optimize Coverage and Payment and Identify Opportunities

Speakers
  • Vice President, Client Services, Quorum Consulting
    Biography
      Nicole Littmann is a leading expert in development and implementation of reimbursement strategy for innovative medical technologies, with over 15 years of experience in health care and public policy, 10 of those years in reimbursement consulting. Ms. Littmann has worked across various diagnostic and therapeutic areas, including molecular pathology, oncology, cardiology/cardiac surgery, and spine/orthopedics. From the time CMS implemented unique payment pathways for new technologies, she has been at the forefront of securing carve-out payment for her clients' technologies under Medicare. She has well-established relationships with payer decision-makers at both coverage and payment policy levels, as well in-depth technical and procedural knowledge of the AMA and CMS processes to secure CPT and HCPCS codes for these technologies. Ms. Littmann has helped manufacturers, providers, and patients navigate the health care system for access to medical innovation through clinical trial coverage and reimbursement, running efficient coding and billing hotlines, and implementing customized, effective appeals programs and patient assistance programs.

    Abstract:
    2013 has proven to be a year of paradigmatic shifts in molecular diagnostics reimbursement policy. In this session, we will review and analyze these key policy and payment developments and discuss how your company can optimize the adoption of novel molecular diagnostic tests by developing strategies that consider the dynamic and changing reimbursement landscape. The key learning objectives from this presentation are as follows:

    - Understand the current coding landscape and potential payment rates for these lab services
    - Learn the implications for the new McKesson/American Medical Association partnership
    - Be aware of coding development for future next-generation sequencing technology
    - Learn about the different levels of evidence that drive coverage for diagnostic tests

    Show Resources
    You May Also Like
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUL 30, 2019 10:00 AM PDT
    C.E. CREDITS
    JUL 30, 2019 10:00 AM PDT
    DATE: July 30, 2019TIME: 10:00am PT/ 1:00pm ET The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high...
    AUG 14, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 14, 2019 09:00 AM PDT
    DATE: August 14, 2019TIME: 9:00am PT. 12:00pm ET Implementation of Lean Methodology in Biobanking Operations to standardize sample management processes is effective. Each proce...
    Loading Comments...
    Show Resources